Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by Sykehuset Innlandet HF.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Sykehuset Innlandet HF
ClinicalTrials.gov Identifier:
NCT01318174
First received: March 17, 2011
Last updated: April 14, 2011
Last verified: February 2011

March 17, 2011
April 14, 2011
April 2011
April 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01318174 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease
Prevalence of Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease

The purpose of this study is to determine the prevalence of pulmonary embolism in our population of Chronic Obstructive Pulmonary Disease (COPD) patients admitted to hospital with dyspnea. The patients will undergo investigation for pulmonary embolism, according to current guidelines.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with known or suspected COPD admitted with an exacerbation of unknown aetiology

  • Pulmonary Embolism
  • Chronic Obstructive Pulmonary Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
April 2012
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • known or suspected COPD
  • COPD-exacerbation

Exclusion Criteria:

  • other causes of dyspnea
  • unable to perform CT pulmonary angio (contrast allergy, pregnancy)
  • already included in the study (each patient included only once)
  • use of anticoagulants
Both
18 Years and older
No
Contact: Aleksander T Holten, PhD +47 48018363 aleksander.holten@sykehuset-innlandet.no
Norway
 
NCT01318174
LE-KE
No
Aleksander Talgøy Holten, PhD, MD, Sykehuset Innlandet HF
Sykehuset Innlandet HF
Not Provided
Principal Investigator: Aleksander T Holten, PhD Sykehuset Innlandet HF
Sykehuset Innlandet HF
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP